Neoadjuvant Immunotherapy for Hepatocellular Carcinoma

Thomas U Marron1 The neoAdjuvant Research Group to Evaluate Therapeutics (TARGET), Icahn School of Medicine at Mount Sinai, New York, NY, USA;2 Early Phase Trials Unit, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;3 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;4 Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;5 Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA;6 Center of Excellence for Liver and Bile Duct Cancer, Icahn School of Medicine at Mount Sinai, New York, NY, USA;7 Liver Cancer Program, Division of Liver Diseases and RM Transplant Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USACorrespondence[email protected]

https://orcid.org/0000-0001-5903-8191

Myron Schwartz1 The neoAdjuvant Research Group to Evaluate Therapeutics (TARGET), Icahn School of Medicine at Mount Sinai, New York, NY, USA;2 Early Phase Trials Unit, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;3 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;4 Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;6 Center of Excellence for Liver and Bile Duct Cancer, Icahn School of Medicine at Mount Sinai, New York, NY, USA;7 Liver Cancer Program, Division of Liver Diseases and RM Transplant Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Virginia Corbett1 The neoAdjuvant Research Group to Evaluate Therapeutics (TARGET), Icahn School of Medicine at Mount Sinai, New York, NY, USA;3 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;5 Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA;6 Center of Excellence for Liver and Bile Duct Cancer, Icahn School of Medicine at Mount Sinai, New York, NY, USA;7 Liver Cancer Program, Division of Liver Diseases and RM Transplant Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Miriam Merad1 The neoAdjuvant Research Group to Evaluate Therapeutics (TARGET), Icahn School of Medicine at Mount Sinai, New York, NY, USA;2 Early Phase Trials Unit, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;3 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;4 Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;5 Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA;6 Center of Excellence for Liver and Bile Duct Cancer, Icahn School of Medicine at Mount Sinai, New York, NY, USA;7 Liver Cancer Program, Division of Liver Diseases and RM Transplant Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Neoadjuvant Immunotherapy for Hepatocellular Carcinoma

Articles from other publishers (6)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Neoadjuvant Immunotherapy for Hepatocellular Carcinoma

Citations (6)

Articles from other publishers (6)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date